Nuclear receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
== Bodily location == In mammals, gluconeogenesis has been believed to be restricted to the liver, the kidney, the intestine, and muscle, but recent evidence indicates gluconeogenesis occurring in astrocytes of the brain. These organs use somewhat different gluconeogenic precursors. The liver preferentially uses lactate, glycerol, and glucogenic amino acids (especially alanine) while the kidney preferentially uses lactate, glutamine and glycerol. Lactate from the Cori cycle is quantitatively the largest source of substrate for gluconeogenesis, especially for the kidney. The liver uses both glycogenolysis and gluconeogenesis to produce glucose, whereas the kidney only uses gluconeogenesis. After a meal, the liver shifts to glycogen synthesis, whereas the kidney increases gluconeogenesis. The intestine uses mostly glutamine and glycerol. Propionate is the principal substrate for gluconeogenesis in the ruminant liver, and the ruminant liver may make increased use of gluconeogenic amino acids (e.g., alanine) when glucose demand is increased. The capacity of liver cells to use lactate for gluconeogenesis declines from the preruminant stage to the ruminant stage in calves and lambs. In sheep kidney tissue, very high rates of gluconeogenesis from propionate have been observed. In all species, the formation of oxaloacetate from pyruvate and TCA cycle intermediates is restricted to the mitochondrion, and the enzymes that convert phosphoenolpyruvic acid (PEP) to glucose-6-phosphate are found in the cytosol.
In chromatography substances are separated by partition between a stationary phase and a mobile phase. The analyte is dissolved in the mobile phase, and passes over the stationary phase. Separation occurs because of differing affinities of the analytes for the stationary phase. A distribution constant, Kd can be defined as
In the chemical industry, carbon dioxide is mainly consumed as an ingredient in the production of urea, with a smaller fraction being used to produce methanol and a range of other products. Some carboxylic acid derivatives such as sodium salicylate are prepared using CO2 by the Kolbe–Schmitt reaction. Captured CO2 could be to produce methanol or electrofuels. To be carbon-neutral, the CO2 would need to come from bioenergy production or direct air capture.
Kombucha is promoted with many claims for health benefits, from alleviating hemorrhoids to combating cancer. Although people may drink kombucha for such supposed health effects (attributed first to the protective impact of tea itself, and to fermentation products including glucuronic acid, acetic acid, polyphenols, phenols, and B-complex vitamins such as folic acid), there is no clinical proof that it provides any benefit. A review found only one human study on kombucha. Kombucha is an "extreme example" of an unconventional remedy because of the disparity between implausible, wide-ranging health claims and the potential risks of the product. It concluded that the proposed, unsubstantiated therapeutic claims did not outweigh known risks, and that kombucha should not be recommended for therapeutic use, being in a class of "remedies that only seem to benefit those who sell them".
Sources: en.wikipedia.org
==== U.S. regulatory restrictions ==== The US Food and Drug Administration (FDA) position is that red yeast rice products that contain monacolin K are identical to a prescription drug and, thus, subject to regulation as a drug. In 1998, the FDA initiated action to ban a product (Cholestin) containing red yeast rice extract. The U.S. District Court in Utah ruled in favor of allowing the product to be sold without restriction. This decision was reversed on appeal to the U.S. Court of Appeals in 2001. In 2007, the FDA sent warning letters to two dietary supplement companies. One was making a monacolin content claim about its RYR product and the other was not, but the FDA noted that both products contained monacolins. Both products were withdrawn. In a press release the FDA "...is warning consumers to not buy or eat red yeast rice products... may contain an unauthorized drug that could be harmful to health." The rationale for "harmful to health" was that consumers might not understand that the dangers of monacolin-containing red yeast rice are the same as those of prescription statin drugs. A products analysis report from 2010 tested 12 products commercially available in the U.S. and reported that per 600 mg capsule, total monacolins content ranged from 0.31 to 11.15 mg. A 2017 study tested 28 brands of red yeast rice supplements purchased from U.S. retailers, stating "the quantity of monacolin K varied from none to prescription strength". Many of these avoid FDA regulation by not having any appreciable monacolin content.
In-space manufacturing uses processes such as additive manufacturing (printing a 3D object in successive layers), subtractive manufacturing (making 3D objects by successively removing material from a solid), hybrid manufacturing (usually combining additive manufacturing and subtractive manufacturing) and welding (joining pieces of material by melting or plasticizing along a joint line). In-space manufacturing removes spacecraft design limitations due to launch parameters (mass, vibration, structural load, etc.) and volume limitations imposed by payload size. It allows for recycling of launched materials, utilization space-mined resources and on-demand spare parts production, which enables on-site repair of critical parts (increasing reliability and redundancy) and infrastructure development. It takes advantage of unique space features such as microgravity, ultra-vacuum and containerless processing, which are difficult to do on Earth.
After the war, the party was refounded, but it was confronted with the emergence of the Christian Democratic Union (CDU), a new party formed as a Christian party comprising both Catholics and Protestants. As many former Centre party politicians, such as Konrad Adenauer, were founding members or joined the CDU, and Cardinal Josef Frings of Cologne endorsed the new party, the party lost its position as the party of the Catholic population. For some time, however, the party managed to hold on to regional strongholds in North Rhine-Westphalia. In 1945, its Rudolf Amelunxen had been the new state's first Minister-President, and it participated in the state government until 1958, when it left the state parliament. Until 1959, the Centre was also represented in the state parliament of Lower Saxony. On the national level, in the elections of 1949, it won ten seats in the first Bundestag. However, in 1953, the party (with the aid from the regional CDU) only retained three seats. In 1957, largely due to the massive CDU landslide that year, the party dropped out of the Bundestag completely and it did not return until 2022. This demise is at least partly because of Helene Wessel. In 1949, she was one of the Centre's representatives in the Bundestag and also was elected chairwoman of the party, the first woman ever to lead a German party. In 1951, she vocally opposed Adenauer's policy of West German rearmament and joined forces with the CDU's Gustav Heinemann, the former Minister of the Interior.
== Identification == S. haemolyticus can be identified on the species level using a variety of manual and automated methods. The most frequently employed are: the reference method (based on growth tests), API ID 32 Staph (bioMe´rieux), Staph-Zym (Rosco), UZA (a rapid 4-h method), and polymerase chain reaction and electrophoretic analysis of the 16S rRNA, hsp60, or sodA gene sequence. Preference towards a particular method usually depends on convenience, economics, and required specificity (some species have identical 16S rRNA). The most closely related species of S. haemolyticus is Staphylococcus borealis.
In any case, the serotonin 5-HT2A receptor antagonist ketanserin blocked not only the psychoactive but also the physical side effects of mescaline including nausea and vomiting, suggesting that these effects may be mediated by serotonin 5-HT2A receptor activation. Mescaline has been found to increase oxytocin levels in humans and to a greater extent than LSD or psilocybin at equivalent doses. There is no evidence of acute tolerance with mescaline. However, tolerance to mescaline builds with repeated use, lasting for a few days. The drug causes cross-tolerance with other psychedelics like LSD and psilocybin. The cryo-EM structures of the serotonin 5-HT2A receptor with mescaline, as well as with various other psychedelics and serotonin 5-HT2A receptor agonists, have been solved and published by Bryan L. Roth and colleagues. Mescaline has been found to bind to tubulin and act as a highly potent mitotic inhibitor similarly to its cyclized derivatives colchicine and demecolcine. Aside from the identification of this action however, it does not appear to have been further studied.
Sources: en.wikipedia.org
Pentachlorophenol in the Pesticide Properties DataBase (PPDB) Non-CCA Wood Preservatives: Guide to Selected Resources - National Pesticide Information Center Archived 2007-10-31 at the Wayback Machine EPA on pentachlorophenol atsdr.cdc.gov on pentachlorophenol CDC – NIOSH Pocket Guide to Chemical Hazards EPA study that used the fungus Phanerochaete chrysosporium to aid in bioremediation of pentachlorophenol in soil[link removed] EPA ReRegistration – www.regulations.gov -Search docket ID EPA-HQ-OPP-2014-0653.
=== Severe intoxication === As of 2007 there is no known antidote or reversal agent for caffeine intoxication. Treatment of mild caffeine intoxication is directed toward symptom relief; severe intoxication may require peritoneal dialysis, hemodialysis, or hemofiltration. Intralipid infusion therapy is indicated in cases of imminent risk of cardiac arrest in order to scavenge the free serum caffeine.
=== 21st century === The current prescribing information for laudanum in the US states that opium tincture's sole indication is as an anti-diarrheal, although the drug is occasionally prescribed off-label for treating pain and neonatal withdrawal syndrome.
== Chemistry == Isavuconazonium comprises an N-(3-acetoxypropyl)-N-methylamino-carboxymethyl group linked through an ester moiety to the triazole nitrogen in isavuconazole. In the aquatic media of the body, the isavuconazole molecule is transformed into monohydrate.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.